Leucovorin News
Pro-Pharmaceuticals Files Phase II Clinical Trial Protocol for First Line Treatment of Colorectal Cancer Patients; Regimen Includes
Newton, Mass.-- Pro-Pharmaceuticals (Amex: PRW), a developer of novel nanotechnology carbohydrate compounds, today announced it has filed a clinical protocol with the U.S. Food & Drug Administration (FDA) for an open-label, up to...
Capecitabine effective alternative to fluorouracil / leucovorin for colon cancer
New York - Treatment of stage III colon cancer with adjuvant capecitabine is at least as effective as fluorouracil plus leucovorin in promoting disease-free survival, according to results of a phase III trial in the June 30th...
Targent Incorporated Reports Transfer of Orphan Drug Designations Relating to Isovorin -L-Leucovorin- for Colon Cancer Indication and for Osteosarcoma
Princeton, N.J.--Targent Incorporated today announced the U.S. Food and Drug Administration (FDA) has authorized the transfer of two Orphan Drug Designations to its lead oncology candidate, Isovorin (L-Leucovorin) for use in the...
Fluorouracil Combinations Comparable in Colon Cancer Outcome
New York - Adjuvant chemotherapy regimens involving fluorouracil in combination with leucovorin, with or without levamisole, appear to achieve similar survival in patients with high-risk colon cancer, according to long-term...
Displaying results 16 to 19 out of 19